Your session is about to expire
← Back to Search
Group G1, Subgroup G1-B for COVID-19
Study Summary
This trial will test if VBI-2901e vaccine is safe and boosts immunity against COVID-19 and other related coronaviruses. It includes 3 dose levels of the vaccine, a single dose or 2-dose regimen.
- COVID-19
- Coronavirus
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
What key aims are researchers targeting with this experiment?
"The primary aim of this trial, assessable over a 28-day period after each vaccination, is to record any medically attended adverse events. Secondary endpoints include measuring the geometric mean titer (GMT) and fold rise (GMFR) in titers against SARS-CoV-2 ancestral strain, variants Beta Delta and Omicron as well as both SARS-CoV1 and MERS CoV at Days 1 7 28 35 56 84 168 336. The GMFR of serum IgG antibodies to Spike Protein and Receptor Binding Domain will also be evaluated using ELISA tests across the same time frame."
Are there any limitations on who can join this investigation?
"This research study is recruiting 60 people aged 18-40 who have been infected with coronavirus. The most pertinent criteria for participants includes: gender, good physical health without chronic medical conditions in the past 6 months, reproductive status (eg. postmenopausal or surgically sterile), agreement to use effective birth control and condoms during the trial period, no prior donation of sperm and previously received 2+ doses of a Health Canada approved COVID-19 vaccine administered 24 weeks before enrollment."
Are there any open opportunities to join this experiment?
"The details on clinicaltrials.gov reveal that this investigation is not presently seeking subjects. The trial was first posted November 1st 2022 and last edited November 10th 2022, though there are still 1050 other trials open to registration at the time of writing."
What risks accompany the administration of Group G3, Subgroup G3-A to patients?
"Given the limited data available in regards to efficacy and safety, our team at Power assigned Group G3, Subgroup G3-A a score of 1 on their scale."
Is eligibility for this trial contingent upon a specific age threshold?
"This medical trial only permits patients between 18 and 40 years old to be enrolled, as stated in the eligibility criteria."
Share this study with friends
Copy Link
Messenger